You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和譽-B(02256.HK)與百濟神州達成合作協定開展ABSK091(AZD4547)與替雷利珠單抗聯合用藥臨牀研究

格隆匯2月15日丨和譽-B(02256.HK)發佈公吿,2022年2月15日,宣佈其在研的泛FGFR抑制劑ABSK091(AZD4547)將與百濟神州自主研發的抗PD-1抗體替雷利珠單抗開展針對尿路上皮癌聯合治療的臨牀研究。

根據披露,ABSK091(AZD4547)是一種高效、選擇性的FGFR亞型FGFR1、2和3抑制劑。對多種FGFR基因改變腫瘤模型的研究顯示,其在體內的療效良好,具有很強的與其他靶向或免疫藥物結合的潛力。和譽生物目前正在中國開展一項針對ABSK091(AZD4547)單藥治療尿路上皮癌的臨牀II期試驗,同時國內外多項臨牀試驗結果表明FGFR抑制劑與抗PD-1抗體聯用對尿路上皮癌效果顯著。

研究報吿顯示,2020年中國尿路上皮癌患者約20萬人,其中約30%具有FGFR異常。研究表明,腫瘤精準及腫瘤免疫藥物的聯合治療,因為其針對不同的作用機制顯示出更高的療效及更好的安全性。公司希望即將開展的ABSK091(AZD4547) 與替雷利珠單抗聯合用藥的研究將進一步加快其在國內的臨牀開發進程,從而儘早將這一極具潛力的新藥療法帶給患者。與百濟神州簽署的臨牀供應協議並不涉及任何金錢對價。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account